Literature DB >> 16763497

Factors associated with recent sildenafil (viagra) use among men who have sex with men in the United States.

Travis H Sanchez1, Kathleen M Gallagher.   

Abstract

BACKGROUND: Previous studies reported associations between sildenafil (Viagra; Pfizer, New York, NY) use and risk behaviors among men who have sex with men (MSM) in limited geographic areas or special populations. The purpose of the present study was to examine Viagra use among a broader MSM population.
METHODS: The 2002 HIV Testing Survey data from MSM recruited at bars in 10 US states was used to examine Viagra use in the 12 months preceding the interview. Independent correlates of Viagra use were identified using logistic regression.
RESULTS: Eleven percent (131/1177) of MSM reported recent Viagra use. Users were older (adjusted odds ratios [aOR] = 2.4 to 6.2, 95% CI: 1.2 to 13.6); were more likely be infected with HIV (aOR = 2.0, CI: 1.0 to 3.9); reported more male sex partners (aOR = 2.4 to 2.7, CI: 1.2 to 5.4); were twice as likely to have unprotected anal intercourse with a nonprimary male partner (aOR = 2.1, CI: 1.2 to 3.5); and were 3 times more likely to report illicit drug usage (aOR = 3.1, CI: 1.9 to 5.2). Fifty-three percent (70/131) of Viagra users simultaneously took illicit drugs.
CONCLUSIONS: Among MSM from numerous US cities, Viagra use is common and is associated with several high-risk behaviors. These findings are consistent with previous reports and emphasize the need for additional prevention counseling for MSM that incorporates messages targeting Viagra usage and risk behavior.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16763497     DOI: 10.1097/01.qai.0000218361.36335.77

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  9 in total

1.  Current sexual activity and risky sexual behavior in older men with or at risk for HIV infection.

Authors:  Nina A Cooperman; Julia H Arnsten; Robert S Klein
Journal:  AIDS Educ Prev       Date:  2007-08

Review 2.  Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy.

Authors:  Daniel Ciccarone
Journal:  Prim Care       Date:  2011-01-11       Impact factor: 2.907

3.  Lessons from the viagra study: methodological challenges in recruitment of older and minority heterosexual men for research on sexual practices and risk behaviors.

Authors:  Sande Gracia Jones; Carol A Pat Patsdaughter; Vicente Manuel Martinez Cardenas
Journal:  J Assoc Nurses AIDS Care       Date:  2011-01-08       Impact factor: 1.354

4.  Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS.

Authors:  David G Ostrow; Michael W Plankey; Christopher Cox; Xiuhong Li; Steven Shoptaw; Lisa P Jacobson; Ronald C Stall
Journal:  J Acquir Immune Defic Syndr       Date:  2009-07-01       Impact factor: 3.731

5.  Associations between substance use, erectile dysfunction medication and recent HIV infection among men who have sex with men.

Authors:  Lydia N Drumright; Pamina M Gorbach; Susan J Little; Steffanie A Strathdee
Journal:  AIDS Behav       Date:  2007-12-07

Review 6.  Use of crystal methamphetamine, Viagra, and sexual behavior.

Authors:  Dennis G Fisher; Grace L Reynolds; Lucy E Napper
Journal:  Curr Opin Infect Dis       Date:  2010-02       Impact factor: 4.915

7.  Motivations for the recreational use of erectile enhancing medications in urban gay and bisexual men.

Authors:  D W Pantalone; D S Bimbi; J T Parsons
Journal:  Sex Transm Infect       Date:  2008-11       Impact factor: 3.519

8.  Quality of life in HIV clinical trials: why sexual health must not be ignored.

Authors:  Olivier Koole; Christiana Noestlinger; Robert Colebunders
Journal:  PLoS Clin Trials       Date:  2007-03-02

9.  Factors associated with reinfection of syphilis in reference centers for sexually transmitted infections.

Authors:  Valéria Correa de Almeida; Maria Rita Donalisio; Ricardo Cordeiro
Journal:  Rev Saude Publica       Date:  2017-06-26       Impact factor: 2.106

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.